Metformin 500 mg + Glimepiride 1 mg (Tab)

Product Overview

YASGLIF-M1 is an advanced oral antidiabetic formulation containing Metformin Hydrochloride 500 mg (PR) and Glimepiride 1 mg. Glimepiride binds to SUR1 receptors on pancreatic beta cells, closing ATP-dependent potassium channels to induce cell depolarization and stimulate basal and postprandial insulin release. Prolonged-release Metformin activates AMPK, reducing hepatic gluconeogenesis and enhancing peripheral muscle glucose uptake.
Designed to offer balanced daily glycemic control, this long-acting combination prompts the pancreas to release insulin when needed after meals, while helping muscle and body tissues absorb and utilize blood sugar more efficiently.
Developed under stringent quality standards, YASGLIF-M1 ensures consistent efficacy, safety, and patient compliance — empowering physicians to achieve optimal therapeutic outcomes in Type 2 Diabetes Mellitus.

Dual mechanism offers enhanced glucose regulation from both hepatic and pancreatic pathways.
Ideal for step-up therapy from monotherapy to combination treatment.
Low-dose Glimepiride minimizes hypoglycemic risk while maintaining efficacy.
Ensures better adherence with once-daily dosing convenience.

Each film-coated tablet contains:

Recommended for patients requiring initial combination therapy or escalation from single-drug regimens.
Provides gradual and sustained glycemic control with fewer side effects.
Demonstrated to improve insulin sensitivity and reduce fasting glucose effectively.
Enhances patient comfort and confidence through predictable therapeutic response.

Part of Yaselle Diaxen – Diabetes & Endocrine Care Division
Committed to advancing endocrine health through evidence-based innovation.